Phase 1 CARDINAL trial evaluating TERN-701 in 2L+ CML patients remains ongoing, with interim data from initial cohorts anticipated in second half of 2024 FOSTER CITY, Calif., April 29, 2024 (GLOBE ...
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small ...
Second candidate from Tenvie’s product engine to enter clinical development Phase 1 first-in-human study to evaluate single and multiple ascending doses of TNV108 in healthy volunteers Preliminary ...
Researchers from Dong-A Socio Holdings Co. Ltd. presented a first-in-class Src homology 2 domain-containing phosphatase 1 (SHP1) allosteric inhibitor, SB-8091, being developed as an anticancer agent.
Researchers from China Pharmaceutical University reported the discovery and preclinical characterization of allosteric inhibitors of Src homology-2-containing protein tyrosine phosphatase 2 (SHP2) as ...
Alumis Inc., a clinical stage biopharmaceutical company, announced that it will present data on its oral therapy A-005, a selective TYK2 inhibitor, at the ACTRIMS Forum 2025 on February 28, 2025.
NEW YORK--(BUSINESS WIRE)--Allosteric Bioscience, Inc. (ABI), has announced today that it has licensed technology from Johns Hopkins University for the treatment or prevention of sarcopenia which is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results